Applied Genetic Technologies Corp., backed by technology from the University of Florida, raises $37.5m in a record area venture round.

Applied Genetic Technologies Corp. (AGTC), a US-based biotechnology company that receives much of its technology licenced from the University of Florida, has raised a $37.5m series B round.

GlaxoSmithKline’s venture unit SR One led the round along with life science venture firm Alta Partners. They were joined by new investor Osage University Partners, a venture fund that invests in university start-ups. Also joining the round were existing venture firm investors Intersouth Partners, InterWest, and MedImmune Ventures.

Intersouth, InterWest, and MedImmune all participated in two previous rounds in 2003 and 2009, which raised $27m and $11.8m, respectively. Venture firm Skyline Ventures also participated in 2003. The company has stated that, in total, the Florida-based firm has raised $88m, including $5.5m in grants.

David Day, director of technology licensing at the University of Florida, said: “These gene therapy products that AGTC is working on are almost like miracles. These are the kinds…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?